Clinical Trial Update: AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cediranib (AZD2171) for locally advanced unresectable or metastatic hepatocellular carcinoma was terminated; results were posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Cediranib (Cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 2 | Status: TERMINATED | Results posted: 2016-10-31